RENB: Rata-rata rega prakiraan Enochian BioSciences

Renovaro Inc. (RENB) is an ambitious developer of personalized therapies whose image is built on the synergy of genetic engineering and AI, with growth driven by vaccine development successes and M&A potential. The stock's price chart reflects a consensus forecast of 0.00. However, a potential cash crunch, pressure from the SEC, and protracted legal disputes that undermine confidence in the biotech's technological platform remain serious concerns.

RENB (Renovaro) riwayat Prakiraan konsensus analis saka 21.02.2024 nganti 01.10.2025

Rincian analitis perusahaan Renovaro Inc. (RENB)

Indikator analitis utama renovarobio.com (RENB):

Bagan owah-owahan rega renovarobio.com|RENB - Prakiraan konsensus analis|Nilai pasar Enochian BioSciences

Analisis fundamental perusahaan:Renovaro Biosciences (RENB)

Produk asli Renovaro Inc.

This indicator represents the weighted average of target prices from independent experts, aggregating market expectations for the asset's fair value based on cash flow analysis. In the case of Renovaro Inc. (RENB), this metric allows for a comparison between the commercialization potential of AI platforms and the oncology pipeline against the current share price, identifying the fundamental floor via the average projected price from investment banks.

Perusahaan pesaing

ONC (beigene.com) - Konsensus nilai wajar|Prakiraan konsensus analis HALO (Halozyme)|Revolution Medicines Inc (RVMD) - Rata-rata rega prakiraan|AAPG - Bagan rega target|CGON (CG Oncology Therapeutics) - Prakiraan gabungan firma investasi|URGN: Prakiraan konsensus analis|BCAX (bicara.com) - Bagan rega target|PSNL (Personalis) - Prakiraan konsensus analis|Target konsensus Erasca Inc (ERAS)|Prakiraan konsensus analis DCTH|Prakiraan konsensus analis Y-mAbs Corp (YMAB)|Bagan rega target Aura Biosciences, Inc. AURA|CADL: Prakiraan gabungan firma investasi|Accuray - Prakiraan konsensus analis|SELLAS Life Sciences (SLS) - Target konsensus|ACTU: Prakiraan konsensus analis|Rata-rata rega prakiraan Citius Oncology Inc (CTOR)|Bagan rega target TuHURA Biosciences Inc.|TARA: Konsensus nilai wajar|Target konsensus FATE (Fate Therapeutics)|WHWK (aadibio.com) - Konsensus nilai wajar|Prakiraan konsensus analis TCRX (TScan Therapeutics, Inc.)|CSBR - Target konsensus|XBIT: Target konsensus|CVM - Prakiraan konsensus analis|OS Therapies (OSTX) - Bagan rega target|Radiopharm Theranostics Ltd - Konsensus nilai wajar|ARTV (Artiva Biotherapeutics Inc.) - Prakiraan konsensus analis|Rata-rata rega prakiraan Adlai Nortye Limited ANL|Bagan rega target Veru Inc. (VERU)|TPST (tempesttx.com) - Konsensus nilai wajar|Prakiraan konsensus analis XLO (Xilio Therapeutics)|Mural Oncology PLC (MURA) - Rata-rata rega prakiraan|KAPA - Bagan rega target|OKUR (OnKure Therapeutics Inc) - Prakiraan gabungan firma investasi|w2.cytomed.sg (GDTC) - Bagan rega target|Rata-rata rega prakiraan Curis (CRIS)|Target konsensus APLM|Bagan rega target THAR|Prakiraan konsensus analis ADVB|Prakiraan konsensus analis Genprex Inc (GNPX)|Bagan rega target Calidi Biotherapeutics, Inc. CLDI|Konsensus nilai wajar SBFM|XBIO - Bagan rega target|Rata-rata rega prakiraan Salarius Pharmaceuticals Inc|PPBT (Purple Biotech Corp) - Target konsensus|American Oncology Network, Inc. - Konsensus nilai wajar|BGNE (BeiGene, Ltd.) - Prakiraan konsensus analis|checkpointtx.com (CKPT) - Target median analis|Bagan rega target Elevation Oncology, Inc. (ELEV)|icadmed.com - Prakiraan gabungan firma investasi|Prakiraan konsensus analis IKNA (Ikena Oncology)|NTBL - Target konsensus|VIRX: Target konsensus|Target median analis morphosys.com MOR|NAYA Biosciences Inc. (NAYA) - Bagan rega target|Ascentage Pharma Group International - Konsensus nilai wajar